St-segment elevation myocardial infarction
Conditions
Interventions
DCB group:Target lesions in DCB group were pretreated according to OCT classification
DES group:The DES group is pretreated in accordance with the current guidelines.
Sponsors
Tangdu Hospital of Air Force Millitary Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 and = 0.1mv (> for 30 minutes, V2 and V3 >= 0.2mv) or newly developed left bundle branch block (LBBB); 3. Elevation of cardiac injury markers (troponin, CK-MB) beyond the 99th percentile of laboratory reference upper limit. 4. Target lesion length < 30mm;The vessel diameter of target lesion is between 2.5mm and 4.0mm. 5. No serious complications (no b-type or higher interlayer, no slow blood flow or reflow, and no residual stenosis < 30%) were found after preconditioning (thrombosis suction, balloon predilation, etc.); 6. Able to understand the purpose of the test, willing to participate in and sign the informed consent, willing to perform invasive imaging Patients were followed up.
Exclusion criteria
Exclusion criteria: 1. Hemodynamic instability; 2. Bifurcation lesions and bridge vascular lesions with left main or three-vessel lesions and branching vessel diameter >= 2.5mm; 3. Distorted or calcified target vessels; 4. Lesions that cannot be treated with PTCA or other interventional techniques; 5. After pre-dilation of the target lesion, residual stenosis >= 30% or TIMI blood flow < grade 3, and/or c-type or c-type or above interlayer appeared; 6. Subjects with severe congestive heart failure or NYHA LEVEL IV heart failure; 7. Women who are pregnant or breastfeeding; 8. Those who plan to undergo surgery within 6 months after surgery; 9. Subjects with a life expectancy of less than 1 year or with factors that make clinical follow-up difficult; 10. Existing or existing patients with severe liver and kidney dysfunction (liver failure, cirrhosis, portal hypertension, active hepatitis); 11. Heart transplant subjects; 12. Aneurysms, arteriovenous malformations and aortic dissection; 13. The researcher judged that the patient had poor compliance and could not complete the study as required; 14. Patients with definite diagnosis of tumor; 15. Patients who are participating in other clinical trials (except for other subjects of this project) but have not reached the time limit of the primary study endpoint; 16. Subjects deemed unfit for inclusion by the researcher for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target failure rate (TLF), including death, including cardiac death, target myocardial infarction, and clinically symptom-driven target revascularization (CD-TLR); | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of MACE at 12 months after surgery was defined as cardiac death, clinically driven target vessel myocardial infarction, and clinically driven target lesion revascularization.;TLR;OCT associated clinical endpoints (TBD); | — |
Countries
China
Contacts
Public ContactLi Yan
Tangdu Hospital of Air Force Millitary Medical University
Outcome results
None listed